

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
------------------	----------------

NATURE OF CONVEYANCE:	ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL
-----------------------	--

CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Oculex Pharmaceuticals, Inc.		01/12/2004	CORPORATION: CALIFORNIA

RECEIVING PARTY DATA	
Name:	Allergan, Inc.
Street Address:	2525 Dupont Drive
City:	Irvine
State/Country:	CALIFORNIA
Postal Code:	92612
Entity Type:	CORPORATION: DELAWARE

PROPERTY NUMBERS Total: 6		
Property Type	Number	Word Mark
Serial Number:	76222028	BDD
Registration Number:	2223223	DDS
Registration Number:	2623871	POSURDEX
Serial Number:	76150751	RDT
Registration Number:	2146646	SURODEX
Registration Number:	2136160	SUROQUIN

CORRESPONDENCE DATA	
Fax Number:	(714)246-4249
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Email:	hinchey_susan@allergan.com
Correspondent Name:	Susan Hinchey
Address Line 1:	Allergan, Inc.
Address Line 2:	2525 Dupont Drive
Address Line 4:	Irvine, CALIFORNIA 92612

ATTORNEY DOCKET NUMBER:	030435-0021
-------------------------	-------------

OP \$165.00 76222028

NAME OF SUBMITTER:

Rhonda DeLeon

Total Attachments: 2

source=Assignme#page1.tif

source=Assignme#page2.tif

TRADEMARK ASSIGNMENT

This Trademark Assignment (hereinafter referred to as "Assignment") dated this 12th day of January, 2004, is by and between Oculex Pharmaceuticals, Inc., a California corporation, which has a principal place of business at 601 West California Avenue, Sunnyvale, California 94086 ("Assignor") and Allergan, Inc., a Delaware corporation, which has a principal place of business at 2525 Dupont Drive, Irvine, California 92612 ("Assignee");

WHEREAS, Assignor has adopted, used, is using, and is, to the best of its knowledge and belief, the owner of the trademarks identified in Schedule A, attached hereto and incorporated herein by this reference, and all other rights appurtenant thereto, including, but not limited to, all common law rights, trade name rights, domain name rights, causes of action, and the right to recover for past infringement (the "Trademarks");

WHEREAS, Assignor has adopted, used, is using, and is, to the best of its knowledge and belief, the owner of the U.S. trademark applications and registrations listed in Schedule B and the foreign trademark applications and registrations listed in Schedule C, attached hereto and incorporated herein by this reference, and all other rights appurtenant thereto, including, but not limited to, all common law rights, trade name rights, domain name rights, causes of action, and the right to recover for past infringement (the "Applications and Registrations");

WHEREAS, Assignor has acquired goodwill associated with and symbolized by the Trademarks and the Applications and Registrations and has not abandoned them;


WHEREAS, Assignee is desirous of acquiring all rights, title, and interest in and to the Trademarks and the Applications and Registrations owned by Assignor; and

WHEREAS, Assignor is willing to assign to Assignee all rights, title, and interest as Assignor may possess in and to the Trademarks and the Applications and Registrations;

NOW, THEREFORE, for good and adequate consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor hereby assigns and sells to Assignee all rights, title, and interest as Assignor may possess in and to the Trademarks and the Applications and Registrations; together with the goodwill symbolized by said Trademarks and the Applications and Registrations.

Oculex Pharmaceuticals, Inc., a California corporation

DATED: January 6, 2004


By: Jeffrey L. Edwards
Title: President

Allergan, Inc., a Delaware corporation

DATED: 1/12/04


By: Martin A. Voet
Title: Assistant Secretary

SCHEDULE A

Trademarks

1. BDD
2. DDS
3. POSURDEX
4. RDT
5. SURODEX
6. SUROQUIN

SCHEDULE B

U.S. Trademark Registrations

<u>COUNTRY</u>	<u>MARK</u>	<u>APPL. NO.</u>	<u>APPL. DATE</u>	<u>REG. NO.</u>	<u>REG. DATE</u>
United States	BDD	76/222,028	March 8, 2001		
United States	DDS	75/297,491	May 23, 1997	2,223,223	February 9, 1999
United States	POSURDEX	76/222,027	March 8, 2001	2,623,871	Sept. 24, 2002
United States	RDT	76/150,751	October 20, 2000		
United States	SURODEX	75/019,153	Nov. 13, 1995	2,146,646	March 24, 1998
United States	SUROQUIN	75/018,231	Nov. 13, 1995	2,136,160	February 10, 1998